Search

Manabu Kurokawa

from Hudson, OH
Age ~51
Get Report
Also known as:
Kurokawa Kurokawa
Phone and address:
7514 Forthampton Cir, Hudson, OH 44236
(919) 490-0767
Related to:
Yoko Kurokawa, 56
Connected to:
Casandra A Kurokawa, 37Kazuo Kurokawa, 62Makoto Kuroki, 53Yasushi Kurosawa, 47Yasuhisa Kurose, 69Ken M Kurosu, 65Thomas P Kurosu, 60Brian M Kurowicki, 47Jim KurowickiBowe Kurowski, 49

Manabu Kurokawa Phones & Addresses

  • 7514 Forthampton Cir, Hudson, OH 44236 (919) 490-0767
  • Norwich, VT
  • 401 Archdale Dr, Durham, NC 27707 (919) 490-0767
  • 5123 Copper Ridge Dr, Durham, NC 27707 (919) 490-0767
  • South Deerfield, MA
  • S Deerfield, MA
  • 1024 New Boston Rd, Norwich, VT 05055 (919) 490-0767

Publications

Us Patents

Phospholipase C Zeta Mediated Oocyte Activation, Compositions For Use Therein, And Assays For Detecting And Identifying Agents For Treating Male Infertility

View page
US Patent:
20080175827, Jul 24, 2008
Filed:
Nov 19, 2007
Appl. No.:
11/942406
Inventors:
Rafael A. Fissore - Amherst MA, US
Pablo Visconti - Amherst MA, US
Manabu Kurokawa - Durham NC, US
Sook-Young Yoon - Amherst MA, US
Daniel R. Grow - Long Meadow MA, US
Teru J. Jellerette - Shutesbury MA, US
Jose Bernardo Cibelli - East Lansing MI, US
Pablo Juan Ross - Bath MI, US
Assignee:
Michigan State University - East Lansing MI
University of Massachussetts - Boston MA
Baystate Health, Inc. - Springfield MA
International Classification:
A61K 48/00
C12N 5/00
C12N 15/00
C12Q 1/68
A01N 1/02
C12Q 1/42
US Classification:
424 9321, 435377, 435455, 435 2, 435 21, 435 6
Abstract:
The invention relates to the use of phospholipase C zeta in inducing or promoting the activation of oocytes, preferably human oocytes, nuclear transfer embryos, parthenogenic embryos, cross species embryos and during in vitro fertilization.The invention further relates to methods of detecting levels of expression of phospholipase c zeta in sperm as a means of detecting male infertility.The invention also relates to the use of phospholipase C zeta to treat male infertility. Still further the invention relates to the recombinant cells that are engineered to express phospholipase C zeta, preferably under inducible conditions.Also, the invention relates to antibodies specific to phospholipase C zeta, preferably human phospholipase C zeta.

Methods Of Identifying And Using Mdm2 Inhibitors

View page
US Patent:
20140336202, Nov 13, 2014
Filed:
Dec 7, 2012
Appl. No.:
14/363346
Inventors:
- Durham NC, US
Manabu Kurokawa - Durham NC, US
Neil Spector - Durham NC, US
Mark Dewhirst - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 31/517
A61K 31/404
G01N 33/50
A61K 31/496
US Classification:
51425405, 514409, 51426624, 435 21
Abstract:
Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.
Control profile
Manabu Kurokawa from Hudson, OH, age ~51 Get Report